{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:09:59Z","timestamp":1781024999946,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T00:00:00Z","timestamp":1271980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:p>Inotuzumab ozogamicin (CMC\u2010544), an antibody\u2010targeted chemotherapeutic agent composed of an anti\u2010CD22 antibody conjugated to calicheamicin, a potent cytotoxic antibiotic, specifically targets the CD22 antigen present in &gt;90% of B\u2010lymphoid malignancies, rendering it useful for treating patients with B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL). This phase I study evaluated the safety, tolerability, efficacy, and pharmacokinetics of inotuzumab ozogamicin in Japanese patients. Eligible patients had relapsed or refractory CD22\u2010positive B\u2010NHL without major organ dysfunction. Inotuzumab ozogamicin was administered intravenously once every 28\u2003days (dose escalation: 1.3 and 1.8\u2003mg\/m<jats:sup>2<\/jats:sup>). All 13 patients had follicular lymphoma, were previously treated with \u22651 rituximab\u2010alone or rituximab\u2010containing chemotherapy, and were enrolled into two dose cohorts (1.3\u2003mg\/m<jats:sup>2<\/jats:sup>, three patients; 1.8\u2003mg\/m<jats:sup>2<\/jats:sup>, 10 patients). No patient had dose\u2010limiting toxicities, and the maximum tolerated dose, previously determined in non\u2010Japanese patients (1.8\u2003mg\/m<jats:sup>2<\/jats:sup>), was confirmed. Drug\u2010related adverse events (AEs) included thrombocytopenia (100%), leukopenia (92%), lymphopenia (85%), neutropenia (85%), elevated AST (85%), anorexia (85%), and nausea (77%). Grade 3\/4 drug\u2010related AEs in \u226515% patients were thrombocytopenia (54%), lymphopenia (31%), neutropenia (31%), and leukopenia (15%). The AUC and C<jats:sub>max<\/jats:sub> of inotuzumab ozogamicin increased dose\u2010dependently with pharmacokinetic profiles similar to non\u2010Japanese. Seven patients had complete response (CR, 54%) including unconfirmed CR, four patients had partial response (31%), and two patients had stable disease (15%). The overall response rate was 85% (11\/13). Inotuzumab ozogamicin was well tolerated at doses up to 1.8\u2003mg\/m<jats:sup>2<\/jats:sup> and showed preliminary evidence of activity in relapsed or refractory follicular lymphoma pretreated with rituximab\u2010containing therapy, warranting further investigations. This trial was registered in ClinicalTrials.gov (NCT00717925). (<jats:italic>Cancer Sci<\/jats:italic> 2010)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2010.01601.x","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T13:08:30Z","timestamp":1272028110000},"page":"1840-1845","source":"Crossref","is-referenced-by-count":50,"title":["Phase I study of inotuzumab ozogamicin (CMC\u2010544) in Japanese patients with follicular lymphoma pretreated with rituximab\u2010based therapy"],"prefix":"10.1111","volume":"101","author":[{"given":"Michinori","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2466"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(91)90029-C"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1134"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1905"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2711.2711","article-title":"Clinical activity of the immunoconjugate CMC\u2010544 in B\u2010cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase I study","volume":"108","author":"Fayad L","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012751"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9117"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.018"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9313"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2010.01601.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2010.01601.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:32:38Z","timestamp":1697412758000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2010.01601.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,20]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1349-7006.2010.01601.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01601.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,20]]}}}